CAGRILINTIDE

Cagrilintide Overview

Cagrilinitide is a long-acting, lipidated, albumin-binding amylin agonist that activates both amylin and calcitonin receptors. It is designed for obesity management and may be used alone or paired with a GLP-1 receptor agonist.

Amylin, naturally co-secreted with insulin, plays a key role in appetite control, satiety, gastric emptying, and glucose regulation.

Why Combine Cagrilinitide With a GLP-1?
When used together with a GLP-1 such as Semaglutide, Cagrilinitide produces a strong synergistic effect—enhancing weight loss significantly more than either therapy alone. Additional benefits reported include improved circulation, reduced blood pressure, enhanced bone formation activity, and vasodilation.

Clinical Outcomes

• 6–10% total weight loss at 26 weeks (Cagrilinitide alone)

• 23–24.4% total weight loss at 68 weeks (Cagrilinitide + Semaglutide)

• Up to 8% additional weight loss compared to Semaglutide alone

Possible Side Effects

• Injection site reactions (redness, swelling, itching, hives)

• Nausea or vomiting

• Constipation or diarrhea

• Fatigue

• Headache

• Heartburn

• Rare: gallbladder stones

Contraindications

Do not use Cagrilinitide if any of the following apply:

• Pregnancy or breastfeeding – Safety has not been established.

• History of pancreatitis – Amylin agonists may increase risk.

• Severe gastrointestinal disorders (e.g., gastroparesis, severe GERD) – Cagri slows gastric emptying.

• Uncontrolled thyroid disease – May worsen metabolic instability.

• Severe kidney or liver impairment – Clearance and metabolism may be affected.

• Active gallbladder disease – Risk of gallstone formation may increase.

• Known hypersensitivity to amylin analogs or any component of the formulation.

• Active or recent eating disorders (e.g., anorexia, bulimia) – Appetite-suppressing effects may be harmful.

Reconstitution and Dosing

Reconstitution:

• Mix Cagrilintide 10mg with 2mL (200 units) of Bacteriostatic Water (BAC Water).
  
  

Cycle:

• 16 weeks ON → 4–6 weeks OFF

Titration Schedule:

• Administer subcutaneously, once weekly

• Week 1: 8 units (400 mcg)

• Weeks 2–3: 15 units (750 mcg)

• Weeks 4–5: 24 units (1.2 mg)

• Weeks 6–7: 34 units (1.7 mg)

• Weeks 8–9: 44 units (2.2 mg)

• Weeks 10–16: 54 units (2.7 mg)

Important Notes:

• Maintain the same dosing day each week

• Stay well-hydrated throughout the cycle

• Avoid exceeding 16 consecutive weeks

• Anti-Cagri antibodies may develop with prolonged use (seen in 46–73% of users)

Recommended Stacks

• Semaglutide or Tirzepatide – Maximizes appetite suppression and enhances fat loss

• Tesofensine – Increases energy expenditure and thermogenesis

• L-Carnitine – Supports fat metabolism and energy conversion

• AOD-9604 – Promotes fat breakdown without impacting blood glucose

Caveat / Disclaimer

• This guide is for educational purposes only and does not replace medical advice.

• Peptides in compounded form are not approved by the FDA or the Philippine DOH for safety, quality, or effectiveness.

• All medications carry risks. Side effects, allergic reactions, or complications may occur.

• Only a licensed healthcare professional can decide if these peptides are safe for you.

• Do not use if you have medical condition or without medical supervision.

• By using these products, you accept that it is provided “as is”, with no guarantee of results, safety, or effectiveness.

• LUMI+ PEPTIDES PH is not responsible for any misuse, side effects, or complications.